Stellate Ganglion Block (SGB) for COVID-19 Acute Respiratory Distress Syndrome (ARDS)
1 other identifier
interventional
5
1 country
1
Brief Summary
The purpose of this study is to understand if it is safe and useful to perform SGB (Stellate Ganglion Block) in patients who have severe lung injury Acute Respiratory Distress Syndrome (ARDS) due to COVID-19 infection.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Apr 2020
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 24, 2020
CompletedFirst Submitted
Initial submission to the registry
May 22, 2020
CompletedFirst Posted
Study publicly available on registry
May 27, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2020
CompletedApril 25, 2025
April 1, 2025
8 months
May 22, 2020
April 22, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Adverse events related to SGB
Adverse events that can atleast unlikely be attributed to SGB
3 Months
All Adverse events
All adverse events related to COVID-19
3 Months
Death
Death due to any cause
3 Months
Secondary Outcomes (3)
Assessment of respiratory/ pulmonary function
3 Months
Radiographic criteria
3 Months
Cardiac function
3 Months
Study Arms (1)
Stellate Ganglion Block (SGB)
EXPERIMENTALClinical Stellate ganglion block
Interventions
The procedure will be done at the bedside in the ICU without interfering with ongoing treatment.
Eligibility Criteria
You may qualify if:
- Subjects age 18 to 80
- Subjects with PCR documented diagnosis of COVID-19 ARDS requiring critical care and transfer to intensive care unit
- Bilateral opacities consistent with pulmonary edema must be present and may be detected on CT or chest radiograph
You may not qualify if:
- Subjects with pre-existing cardiac failure
- Hemodynamic Instability
- Subject on Extracorporeal membrane oxygenation (ECMO)
- Anatomical inability to do a stellate block
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
West Virginia University Rockefeller Neuroscience Institute
Morgantown, West Virginia, 26506, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Ali R Rezai, MD
West Virginia University
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Director
Study Record Dates
First Submitted
May 22, 2020
First Posted
May 27, 2020
Study Start
April 24, 2020
Primary Completion
December 31, 2020
Study Completion
December 31, 2020
Last Updated
April 25, 2025
Record last verified: 2025-04